SAFC Pharma has commissioned a new suite at its St. Louis campus that will produce high-potency active pharmaceutical ingredient (HPAPI) conjugates to support oncology drug development. The 600-sq.-ft. suite will enable the conjugation of HPAPIs to a variety of targeted delivery molecules, including monoclonal antibodies. The new facility can also accommodate early-stage clinical supplies and can handle multi-kilogram quantities, with the capability to expand production up to commercial-scal...